ABSTRACT
OBJECTIVE@#To explore the therapeutic effect and the mechanism of the adjuvant treatment with moxibustion on coronavirus disease 2019 (COVID-19).@*METHODS@#A total of 95 patients with COVID-19 were randomly divided into a moxibustion group (45 cases) and a basic treatment group (50 cases). The routine treatment of western medicine was applied in the patients of both groups. In the moxibustion group, on the base of the treatment of western medicine, moxibustion was applied to Dazhui (GV 14), Feishu (BL 13), Qihai (CV 6) and Zusanli (ST 36), once daily and consecutively for 14 days. At the end of treatment courses, clinical symptom scores for cough, asthmatic breathing, chest oppression and short breath, as well as their remission rates were compared between the two groups before and after treatment. Before and after treatment, the white blood cell (WBC) count, the levels of c-reactive protein (CRP) and interleukin-6 (IL-6) and the absolute number of T lymphocyte subsets, i.e. , and of the peripheral blood were compared in the patients between the two groups. The principal component analysis was adopted to analyze the common data extracted from the above 10 clinical indexes variables and comprehensively evaluate the differences in the therapeutic effect of two regimens.@*RESULTS@#The clinical symptom scores were all decreased after treatment in both of the moxibustion group and the basic treatment group as compared with those before treatment (@*CONCLUSION@#On the base of the routine treatment with western medicine, moxibustion therapy supplemented relieves the clinical symptoms, reduces the levels of inflammatory indexes, i.e. IL-6 and CRP as well as improves the absolute number of peripheral T lymphocyte subsets. The clinical therapeutic effect of such regimen with moxibustion supplemented is significantly better than the simple routine treatment of western medicine.
Subject(s)
Humans , Acupuncture Points , C-Reactive Protein/analysis , COVID-19/therapy , Inflammation/therapy , Interleukin-6/blood , Leukocyte Count , Moxibustion , T-Lymphocyte Subsets/cytologyABSTRACT
OBJECTIVE: To evaluate the status of application of continuous renal replacement therapy (CRRT) in patients in the intensive care unit (ICU). METHODS: The clinical data of 171 ICU patients who had indications for CRRT in the First Affiliated Hospital of Xi'an Jiaotong University from January to December 2014 were retrospective analyzed. The patients were divided into non-CRRT group (n=23) and CRRT group (n=148) which was composed of continuous veno-venous hemofiltration (CVVH) group (n=66) and non-CVVH group (n=82). Among the 148 CRRT patients, 83 had improvement, 46 had no improvement, and 19 died. Among the 66 CVVH patients, 39 had improvement, and 27 had no improvement. The indications of the 171 patients and several aspects of the CRRT group including anticoagulation regimen, catheterization program, replacement fluid, and CRRT pipe flushing were statistically analyzed. And the correlations between the clinical data, CRRT mode, and efficacy were evaluated. RESULTS: The rate of rational indications of 171 patients was 86.55%, meanwhile the rates of the reasonability of anticoagulation method, catheterization program, replacement fluid, and CRRT pipe flushing of the CRRT group were 84.76%, 66.89%, 100%, and 100%, respectively. Single factor analysis showed that the levels of BUN (P=0.035) and creatinine (P=0.007) at baseline and the urine output on the third day (P=0.034) had statistically significant difference among the CVVH group, non-CVVH group, and non-CRRT group. There were also significant differences in the survival rate (P=0.01) and prognosis of survivals (P=0.007) in CRRT group among different catheterization programs. Multivariate analysis indicated that there was significant correlation between the lengh of stay in ICU [P=0.005, OR: 0.734, 95% CI(0. 592, 0.910)], catheterization program [P=0.016, OR: 5.302, 95%CI(1.369, 20.527)] and prognosis. CONCLUSION: The indications, anticoagulation method, and catheterization program of the CRRT group were partially unreasonable in the 171 patients in our study, and the unreasonability rates were 13.45%, 15.24%, and 33.11%, respectively. Clinical pharmacists should focus on the drug regimens and individual monitoring of ICU patients in the process of CRRT, considering their pathophysiological characteristics and complexity of medical therapeutic schemes.
ABSTRACT
· AlM: To investigate the correlation of retinal vein occlusion ( RVO ) with blood lipids and carotid artery changes. · METHODS: Forty cases ( 40 eyes ) with RVO who presented to Eye Hospital of Xinxiang Medical University between May 2013 and April 2014 were selected as the research objects. Proceeded blood lipids and color doppler ultrasonography examination, including total cholesterol ( TC ) , triglycerides ( TG ) , high -density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol ( LDL-C ) , common carotid artery intima-media thickness, carotid plaques, internal carotid artery blood flow mechanics parameters were detected.Thirty eyes ( 30 cases ) were enrolled as control underwent above examinations. ·RESULTS:TC, TG, LDL-C of RVO group was obviously higher than those of the control group ( P0.05 ) . There were also no statistical difference between ipsilateral and contralateral carotid artery measured value of control group (P>0.05).There were no differences in age, sex between RVO group and control group (P>0.05). · CONCLUSlON: Lipid metabolism disorder, carotid artery changes is closely related to the pathogenesis of RVO.
ABSTRACT
Alzheimer's disease (AD) is a complex neurodegenerative disorder which seriously causes the dementia in elderly people and afflicts millions of people worldwide. Drug discovery for Alzheimer's disease therapy has been a hot research area and a big challenge, in which development of acetylcholinesterase (AChE) inhibitors design was the most active and some AChE inhibitors are commercially available for AD medication already. However, practical using of commercial AChE inhibitors showed their limited usefulness and related adverse effects. Thus, it is extremely urgent to find novel AChE inhibitors with higher potency and less adverse effects. Based on the accurate crystallographic studies about AChE, strategies for multi-binding site AChE inhibitors have been formed, followed by design of the multi-target directed ligands. In this review, the structures and binding modes of commercial AChE inhibitors were briefly discussed, together with the development of AChE inhibitor design for AD therapy: from multi-binding site inhibitors to multi-target directed ligands.
Subject(s)
Animals , Humans , Acetylcholinesterase , Chemistry , Metabolism , Alzheimer Disease , Drug Therapy , Amyloid Precursor Protein Secretases , Amyloid beta-Peptides , Metabolism , Aspartic Acid Endopeptidases , Binding Sites , Butyrylcholinesterase , Chemistry , Metabolism , Cholinesterase Inhibitors , Chemistry , Pharmacology , Therapeutic Uses , Drug Design , Ligands , Monoamine Oxidase Inhibitors , Chemistry , Receptors, N-Methyl-D-Aspartate , Structure-Activity RelationshipABSTRACT
Polymerase chain reaction (PCR) is one of the common techniques in molecular biology, which can amplify nucleic acids through the cycle of denaturation, annealing and extension. Based on the principle of common PCR, rapid PCR is to realize the amplification of nucleic acids in less time without affecting the specificity, sensitivity and fidelity of the reaction. A lot of research work in this field has been going on in recent years. This article will make a review of the development of rapid PCR with emphases on the improvement of DNA polymerase, the choice of additives and the improvement of thermocyclers.